PCSK9 and familial hypercholesterolemia: Our data argue for events occurring at the level of the PAF activation pathway as helping understand (1) the role of PCSK9 in enhanced in vivo platelet activation, and (2) the prevention of cardiovascular events in hypercholesterolemia by PCSK9 inhibitor administration [69].